Table 1. Clinical and pathological features of MM patients analysed.
Sample | Age | Sex | DS Stage | ISS Stage | Paraprotein Type | % PCs | Karyotype | New Diagnoses | Bone Disease |
---|---|---|---|---|---|---|---|---|---|
(A) | |||||||||
MM 1 (SaMMi) | 81 | F | IA | III | Micromolecular, λ | 20 | Abnormal karyotype; chr. 1 rearrangement; t(11;14) | Y | N |
MM 2 | 81 | F | IA | III | IgG/k | 46 | Normal | Y | N |
MM 3 | 60 | F | IIA | II | IgG/k | 80 | Normal | N | Y |
MM 4 | 77 | F | IIA | I | IgA/k | 36.9 | 59% del(17p) | Y | Y |
MM 5 | 74 | M | IA | III | IgG/k | 63.8 | del(13q) | N | N |
MM 6 | 58 | M | IIIA | I | IgG/λ | 20 | Normal | N | Y |
MM 7 | 72 | M | IIA | I | IgG/k | 30 | del(17p) | Y | Y |
MM 8 | 58 | M | IIIA | III | IgA/k | 16 | Monosomy 13 (90%) | Y | Y |
MM 9 | 71 | F | IIIA | III | IgG/k | 19 | Normal | Y | Y |
MM 10 | 76 | M | IIA | III | IgG/k | 45 | IgH rearrangement | N | N |
MM 11 | 74 | M | IIIA | II | IgG/λ | 56 | Trisomy 1q, 7, 13, 19, 22; tetrasomy 15, del(8p), del(8p), t(2;3) |
Y | Y |
MM 12 | 64 | M | IIIB | III | IgD/λ | 80 | Complex karyotype; t(11;14), t(1;14), del(13) | Y | Y |
MM 13 | 71 | F | IIA | I | IgG/λ | 30 | Partial del(1); partial 1q trisomy | Y | Y |
MM 14 | 60 | M | IIIA | I | IgG/k | 40.6 | IgH rearrangement, del(13q) | N | Y |
MM 15 | 68 | F | IA | I | IgG/λ | 50 | Normal | N | N |
MM 16 | 60 | F | IA | I | IgA/λ | 51.7 | Complex karyotype; del(1p); presence of hyperdiploid clones |
N | Y |
MM 17 | 67 | F | IIIA | III | Non secretory | 100 | Monosomy 13 (76%) | Y | Y |
MM 18 | 68 | F | IIIA | III | Micromolecular, k | 80 | Normal | N | Y |
MM 19 | 69 | M | IIIA | II | Micromolecular, k | 60 | del(13q), MAF+, IgH-/+ | Y | Y |
MM 20 | 71 | M | IIIA | III | IgG/λ | 90.1 | del(Y), del(13q) | N | Y |
MM 21 | 81 | M | IIIA | II | Micromolecular, λ | 35 | NA | Y | Y |
MM 22 | 76 | F | IIIA | I | IgG/k | 95 | Trisomy 5, 6, 9, 11, 15, 21 | Y | Y |
MM 29 | 44 | M | IIIB | III | IgA/λ | 24 | Complex karyotype; Monosomy 13, 14, 90% del(17p); Chr. 1 rearrangements, gain of 1q | N | Y |
MM30 | 76 | M | IA | NA | IgG/k | 60 | Normal karyotype, IgH rearr., trisomy 17 | Y | N |
MM31 | 72 | F | IIIA | III | IgG/λ | 100 | Complex karyotype, hyperploid; del(13q) | Y | N |
MM32 | 67 | M | IIIA | II | IgG/λ | 100 | NA | Y | Y |
MM33 | 75 | M | IIIB | III | IgG/λ | 40-100 | Hypodiploid , t(14;16), del(13q), gain of 1q | Y | N |
MM34 | 74 | M | IIIB | III | Micromolecular, λ | 100 | IgH-; del(17p), gain of 1q | Y | Y |
MM35 | 56 | M | IIIA | NA | IgG/λ | 100 | NA | N | Y |
MM36 | 42 | F | IIIA | III | IgA/k | 90 | Normal | N | Y |
MM37 | 56 | M | IIIA | I | IgA/l | 100 | Complex karyotype (+1, del(1), dic(1;5), -13,-16, +17. FISH: del(1q), del(13q), del FGFR | N | Y |
MM38 | 70 | M | IIA | II | IgG/λ | 20 | NA | N | Y |
MM39 | 74 | M | IIA | II | IgG/k | 100 | 46XY; t(11;14); gain of 1q | N | Y |
MM40 | 75 | F | IIIA | II | IgG/k | 100 | Complex karyotype; del(6p), del(17p), monosomy 10, 12, 13, 15, 16, 17 | N | Y |
(B) | |||||||||
MM 8 | 58 | M | IIIA | III | IgA/k | 16 | Monosomy 13 (90%) | Y | Y |
MM 14 | 60 | M | IIIA | I | IgG/k | 40.6 | IgH rearrangement, del(13q) | N | Y |
MM 23 | 59 | M | IIIA | I | IgG/k | 44 | Trisomy 1, 5, 9, 18, 19, 21 | Y | Y |
MM 24 | 45 | F | IIIA | III | IgG/k | 86 | 90% MAF-/+, Monosomy 13 | N | Y |
MM 25 | 54 | F | IIA | I | IgG/k | 22 | t(4;14), Monosomy 13 | N | Y |
MM 26 | 74 | F | IA | I | IgG/k | 26.4 | t(14;16) | N | Y |
MM 27 | 76 | F | IIA | III | IgG/λ | 22.8 | Normal | N | Y |
MM 28 | 75 | M | IIB | III | IgG/λ | 14 | 36% del(Y), Monosomy 13 | Y | Y |
MM plasma cells (A) and MM BMSC (B) were isolated from bone marrow of patients listed. Clinical staging was performed according to Durie-Salmon criteria and according to the International Staging System (ISS; albumin levels ≤ or > 35 g/L; β2-microglobulin levels ≤ or > 3.5 mg/L). All features are reported as data at diagnosis. M = Male, F = Female, DS = Durie-Salmon, ISS = International Staging System, PC = Plasma Cell, Y = Yes/Present, N = No/Absent, NA = Not Available.